Predictive Value of PCA3 in Urinary Sediments in Determining Clinico-Pathological Characteristics of Prostate Cancer

被引:127
作者
Hessels, Daphne [2 ]
van Gils, Martijn P. M. Q.
van Hooij, Onno
Jannink, Sander A. [2 ]
Witjes, J. Alfred
Verhaegh, Gerald W.
Schalken, Jack A. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Urol, NL-6500 HB Nijmegen, Netherlands
[2] NovioGendix, Nijmegen, Netherlands
关键词
Gleason score; predictive value; prostate cancer antigen 3; prostate cancer; urine; RADICAL PROSTATECTOMY; ASSAY; MEN; DD3(PCA3); DIAGNOSIS; PATTERNS; BIOPSY; TRENDS; SCORE;
D O I
10.1002/pros.21032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE. PCA3 urine tests have shown to improve the specificity in prostate cancer (PCa) diagnosis, and have thus the potential to reduce the number of unnecessary prostate biopsies and to predict repeat biopsy outcomes. In this study, PCA3 was correlated with clinical stage, biopsy Gleason score (GS), radical prostatectomy GS, tumor volume, and pathological stage to assess its potential as predictor of PCa aggressiveness. METHODS. In this study, 351 men admitted for prostate biopsies based on serum PSA levels > 3 ng/ml, an abnormal DRE, and/or a family history of PCa were included. Post-DRE urinary sediments from 336 men were tested using a transcription-mediated amplification-based PCA3 test, and assay results were correlated with clinical stage and biopsy GS. In a sub-cohort of 70 men who underwent radical prostatectomy, the PCA3 values were correlated to their radical prostatectomy GS, tumor volume, and pathological stage. RESULTS. In this patient cohort we Could not find a correlation between clinical stage, biopsy GS, radical prostatectomy GS, tumor volume, and pathological stage. CONCLUSIONS. The predictive value of PCA3 for PCa aggressiveness features as reported in earlier studies cannot be confirmed in our study. Experimental differences (urine sediments vs. whole urine) and cohort may explain this. The exact place of PCA3 as prognostic test for PCa remains the subject of investigation. Prostate 70: 10-16, 2010. (c) 2009 Wiley-Liss. Inc.
引用
收藏
页码:10 / 16
页数:7
相关论文
共 24 条
  • [1] Bussemakers MJG, 1999, CANCER RES, V59, P5975
  • [2] de Kok JB, 2002, CANCER RES, V62, P2695
  • [3] PCA3: A molecular urine assay for predicting prostate biopsy outcome
    Deras, Ina L.
    Aubin, Sheila M. J.
    Blase, Amy
    Day, John R.
    Koo, Seongjoon
    Partin, Alan W.
    Ellis, William J.
    Marks, Leonard S.
    Fradet, Yves
    Rittenhouse, Harry
    Groskopf, Jack
    [J]. JOURNAL OF UROLOGY, 2008, 179 (04) : 1587 - 1592
  • [4] Estimates of the cancer incidence and mortality in Europe in 2006
    Ferlay, J.
    Autier, P.
    Boniol, M.
    Heanue, M.
    Colombet, M.
    Boyle, P.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (03) : 581 - 592
  • [5] uPM3, a new molecular urine test for the detection of prostate cancer
    Fradet, YF
    Saad, F
    Aprikian, A
    Dessureault, J
    Elhilali, M
    Trudel, C
    Måsse, B
    Piché, L
    Chypre, C
    [J]. UROLOGY, 2004, 64 (02) : 311 - 315
  • [6] PSA in the new millennium: A powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes - Results from the SEARCH database
    Freedland, Stephen J.
    Hotaling, James M.
    Fitzsimons, Nicholas J.
    Presti, Joseph C., Jr.
    Kane, Christopher J.
    Terris, Martha K.
    Aronson, William J.
    Amling, Christopher L.
    [J]. EUROPEAN UROLOGY, 2008, 53 (04) : 758 - 766
  • [7] Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer
    Gallina, Andrea
    Chun, Felix K. -H.
    Suardi, Nazareno
    Eastham, James A.
    Perrotte, Paul
    Graefen, Markus
    Hutterer, Georg
    Huland, Hartwig
    Klein, Eric A.
    Reuther, Alwyn
    Montorsi, Francesco
    Briganti, Alberto
    Shariat, Shahrokh F.
    Roehrborn, Claus G.
    de la Taille, Alexandre
    Salomon, Laurent
    Karakiewicz, Pierre I.
    [J]. BJU INTERNATIONAL, 2008, 101 (12) : 1513 - 1518
  • [8] APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer
    Groskopf, Jack
    Aubin, Sheila M. J.
    Deras, Ina Lim
    Blase, Amy
    Bodrug, Sharon
    Clark, Craig
    Brentano, Steven
    Mathis, Jeannette
    Pham, Jimmykim
    Meyer, Troels
    Cass, Michelle
    Hodge, Petrea
    Macairan, Maria Luz
    Marks, Leonard S.
    Rittenhouse, Harry
    [J]. CLINICAL CHEMISTRY, 2006, 52 (06) : 1089 - 1095
  • [9] Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy
    Haese, Alexander
    de la Taille, Alexandre
    van Poppel, Hendrik
    Marberger, Michael
    Stenzl, Arnulf
    Mulders, Peter F. A.
    Huland, Hartwig
    Abbou, Clement-Claude
    Remzi, Mesut
    Tinzl, Martina
    Feyerabend, Susan
    Stillebroer, Alexander B.
    van Gils, Martijn P. M. Q.
    Schalken, Jack A.
    [J]. EUROPEAN UROLOGY, 2008, 54 (05) : 1081 - 1088
  • [10] DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer
    Hessels, D
    Gunnewiek, JMTK
    van Oort, I
    Karthaus, HFM
    van Leenders, GJL
    van Balken, B
    Kiemeney, LA
    Witjes, JA
    Schalken, JA
    [J]. EUROPEAN UROLOGY, 2003, 44 (01) : 8 - 15